GlaxoSmithKline is launching what it calls the Oncology Clinical and Translational Consortium, a collaborative scientific research network intended to advance drug discovery that will include 6 cancer centers around the world.
With pressure mounting on drugmakers to make clinical trial data more transparent, Pfizer has started to take steps to open up its results, unveiling more concrete details and a timeline for adoption this week.
After settling much of the litigation tied to the health effects on newborns whose mothers took the antidepressant Paxil during pregnancy, maker GlaxoSmithKline has now won a wrongful death case brought by a woman who said she aborted after she was told her fetus had congenital heart defects.
U.K. Prime Minister David Cameron thinks GlaxoSmithKline is a "very decent and strong British business" and has been talking it up with Chinese officials during his trade visit there.
A little more than two months after GlaxoSmithKline abandoned its $1.5 billion partnership on ChemoCentryx's lead drug, the Crohn's drug vercirnon, scrapping three late-stage studies after the first Phase III flopped, the biotech says that GSK has begged off pursuing a follow-up anti-inflammatory program and returned another drug--CCX354--licensed out four years ago.
GlaxoSmithKline CEO Andrew Witty is on his first trip to China since authorities there alleged his company funneled $490 million in bribes to doctors. Despite the scandal, GSK says it remains committed to doing business in China.
Drugmaker GlaxoSmithKline is sending R&D folks into new areas to look for drugs, launching satellite innovation centers in Cambridge, MA, and San Diego.
GlaxoSmithKline is broadening its reach in the big U.S. R&D field in coming months, ramping up satellite innovation centers in Cambridge, MA, and San Diego where its teams can shepherd a growing flock of research partnerships while hunting down new technologies and spawning biotech startups.
A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.
The FDA did a hard about-face today on GlaxoSmithKline's diabetes drug Avandia, deciding that the drug presents no more heart risk than the most commonly used Type 2 diabetes drugs and withdrawing the label warnings and other restrictions.